Navigation Links
BioMS Medical Announces 2008 Year End Results
Date:3/17/2009

and development expenses for the year ended December 31, 2008 totaled $46.5 million compared with $38.9 million in 2007. Research and development expenses were $13.9 million for the three months ended December 31, 2008 compared to $9.3 million for the same quarter the previous year. The increase in expenses was the net result of: achieving full enrolment of clinical sites and patients in the MAESTRO-03 trial; increased costs for the MAESTRO-02 trial as patients enter the trial; reduced costs of the MAESTRO-01 and MINDSET-01 trials as more patients complete these trials; a decrease in drug manufacturing expenses as the manufacture of validation batches is completed; a licensing bonus payment related to the Agreement with Lilly, and; additional expenses related to alliance management and support.

At December 31, 2008, cash and cash equivalents and short-term investments totaled $90.4 million as compared to $37.9 million at December 31, 2007. At December 31, 2008, the Company had working capital of $81.3 million as compared to $32.8 million at December 31, 2007. Management estimates that the current working capital is sufficient for the Company to meet its obligations in respect of the currently initiated clinical trials.

As at December 31, 2008 there were 91,009,323 Class "A" common shares of the Company issued and outstanding.

    About BioMS Medical Corp.
    -------------------------

BioMS Medical is a biotechnology company engaged in the development and commercialization of novel therapeutic technologies. BioMS Medical's lead technology, dirucotide, is for the treatment of multiple sclerosis and is being evaluated in two pivotal phase III clinical trials for Secondary Progressive MS patients, MAESTRO-01 in Canada and Europe and MAESTRO-03 in the United States. In December 2007, BioMS entered into a licensing and development agreement granting Eli Lilly and Company exclusive worldwide rights to dirucotide in exchan
'/>"/>

SOURCE BioMS Medical Corp.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related biology technology :

1. BioMS Medical warrant extension
2. BioMS Medical to present at BIO CEO and Investor Conference
3. BioMS Medical reports results of exploratory phase II trial of dirucotide in relapsing remitting multiple sclerosis
4. BioMS Medical recognized at Scrip Awards 2008
5. BioMS Medical Announces Third Quarter 2008 Results
6. BioMS Medical to present at Rodman and Renshaw Annual Healthcare Conference
7. BioMS Medicals relapsing-remitting multiple sclerosis trial receives positive review from Data Safety Monitoring Board
8. BioMS Medicals phase III U.S. multiple sclerosis trial receives positive safety review from Data Safety Monitoring Board
9. BioMS Medical announces receipt of milestone payment from Eli Lilly and Company
10. BioMS Medical to present at Sachs Associates Biotech in Europe Forum
11. BioMS Medical to present at UBS Global Life Sciences Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/23/2014)... July 23, 2014 OncLive® is ... Center has joined its Strategic Alliance Partnership program. ... Partnership program, UNC Lineberger will have the opportunity ... awareness of its cutting-edge research initiatives, community-directed cancer ... Lineberger will work with OncLive to educate their ...
(Date:7/23/2014)... July 23, 2014 Adult stem ... therapies are biological, but not magical. However, ... to treat them as if they were magical. ... unsanctioned studies that constitute “stem cell tourism,” are ... approach to developing new regenerative medicine therapies. In ...
(Date:7/22/2014)... 2014 (PRWEB) July 23, 2014 ... University. , The goal of the Symposium ... full spectrum of scientists working in the biomaterials ... topics that represent the most promising directions for ...     Provide faculty and government scientists ...
(Date:7/22/2014)... Even within a phylum so full of mean little ... arthropods for its cruelty -- at least to crickets. Native ... is a most predatory sort of parasite. It swoops onto ... of larvae, and leaves its wicked brood to invade, kill ... of this would be possible without the fly,s ability to ...
Breaking Biology Technology:OncLive Expands Its Strategic Alliance Partnership Program With the Addition of UNC Lineberger Comprehensive Cancer Center 2OncLive Expands Its Strategic Alliance Partnership Program With the Addition of UNC Lineberger Comprehensive Cancer Center 3The Adult Stem Cell Technology Center, LLC Continues to Develop Technologies for Homologous Adult Stem Cell Therapies and Drug Development 2The Adult Stem Cell Technology Center, LLC Continues to Develop Technologies for Homologous Adult Stem Cell Therapies and Drug Development 3The Adult Stem Cell Technology Center, LLC Continues to Develop Technologies for Homologous Adult Stem Cell Therapies and Drug Development 4The Adult Stem Cell Technology Center, LLC Continues to Develop Technologies for Homologous Adult Stem Cell Therapies and Drug Development 5The 2014 NJ Symposium on Biomaterials Science Earns Society for Biomaterials Endorsement 2Fly-inspired sound detector 2Fly-inspired sound detector 3Fly-inspired sound detector 4
... , June 15 /PRNewswire-Asia/ -- AgFeed Industries, Inc. ... hog production and animal nutrient companies in China , ... the first phase of the Xinyu production pod starting in ... a division of Genus PLC (LSE: GNS). This stocking will ...
... Cellular ... of bringing more relevant and highly predictive toxicity testing to the drug discovery process. ... Madison, ... into a research collaboration with the goal of bringing more relevant and highly predictive ...
... ... the life sciences industry that incorporates distinctive features and functionality , ... (PRWEB) June 15, ... life sciences industry, today announced the release of Version 2.0 of its Interactive ...
Cached Biology Technology:AgFeed Industries, Inc. Announces Stocking Agreement for Xinyu Production Pod 2AgFeed Industries, Inc. Announces Stocking Agreement for Xinyu Production Pod 3AgFeed Industries, Inc. Announces Stocking Agreement for Xinyu Production Pod 4Promega and Cellular Dynamics Partner to Validate Stem Cell-Based In Vitro Assays for Predicting Drug-Induced Cardiotoxicity 2Promega and Cellular Dynamics Partner to Validate Stem Cell-Based In Vitro Assays for Predicting Drug-Induced Cardiotoxicity 3Viscira Announces Version 2.0 of its Online Interactive Slide Kit Builder Application 2Viscira Announces Version 2.0 of its Online Interactive Slide Kit Builder Application 3
(Date:7/23/2014)... Currently, no cure exists for Alzheimer,s disease, the ... Americans. But scientists are now reporting new progress ... cancer treatment, that shows promise as a potential ... ACS, Journal of Medicinal Chemistry . , ... that in a healthy brain, the protein known ...
(Date:7/23/2014)... preconditioning has been confirmed by many studies, but ... released in the Neural Regeneration Research ... and co-workers from Tongji Hospital Affiliated to Tongji ... China performed cerebral ischemic preconditioning in rats by ... mechanism underlying the neuroprotective effect of ischemic preconditioning. ...
(Date:7/22/2014)... The exhibit consists of both still images and ... of scientific research. Forty-four still images were chosen ... students, postdocs, staff, and alumni representing more than ... from more than 50 submissions. , Zach Donnell, ... of the 2014 organizers, noted that the exhibit ...
Breaking Biology News(10 mins):Art of Science 2014 2
... 16, 2010 Primary care physicians agree they have a ... the right weight management resources. Obese or heavier adults ... lose weight may lack information about effective weight loss methods ... research commissioned and released today by the Strategies to Overcome ...
... programs to safeguard them from getting out of control ... cancer. Until now, researchers assumed that these protective systems ... first time, using an animal model for lymphoma, cancer ... the Charit University Hospital Berlin in Germany have ...
... to passive smoking are more likely to have health problems ... levels of nucleated red blood cells in the umbilical cord ... and Public Health . Pediatrician Abd ElBaky of the ... Cairo University, Egypt, have found that obesity and passive smoking ...
Cached Biology News:STOP Obesity Alliance surveys show doctors, patients share role in weight loss, but ask, now what? 2STOP Obesity Alliance surveys show doctors, patients share role in weight loss, but ask, now what? 32 at 1 stroke -- how cells protect themselves from cancer 2Obesity and passive smoking reduce oxygen supply to unborn baby 2
... Signet offers the most comprehensive, ... requirements. We have incorporated unprecedented quality ... capabilities. This includes proven detection chemistries ... to the TechMate protocol. It also ...
... Each Signet Level 2 Detection System ... avidin-biotin chemical bonding principle and Signets ... provide sensitivity, specificity and reliablility. Signet ... in both manual and automated protocols. ...
... Signet Level 2 Detection System combines ... chemical bonding principle and Signets unique ... sensitivity, specificity and reliablility. Signet reagents ... both manual and automated protocols. ...
Each bottle contains: Bromophenol Blue 0.25% w/v , Xylene Cyanol FF 0.25%, Glycerol solution 30% w/v...
Biology Products: